Tetrous, Inc.

Resources

EnFix RC™ Brochure

Download the EnFix brochure for a full summary of how EnFix RC™  and EnFix TAC™ enhance rotator cuff injury healing at the enthesis and the technologies and techniques involved. 

EnFix Brochure 2024 rev 01 Draft v2

EnFix RC™ Rotator Cuff Procedure

Play Video

Certificates

Tetrous distribution is through Millstone Medical Outsourcing.  Below are links to Millstone’s certifications.

Tetrous manufacturing is through Origin Biologics.  Below are links to Origin Biologics’ Tissue Bank certifications.

Tetrous’s Exemption from registration is explained in the letter below.  Click to download the PDF.

IFU

This website provides Instructions for Use (IFU) documents for products offered by Tetrous, Inc. These prescription-use products are intended for use by healthcare professionals only. The IFU documents on this site are valid only on the date printed. Responsibility resides with the healthcare professional to print the IFU document on the day the product is intended to be used to ensure the most current IFU is referenced.
 
Clinical indications of products published on the Tetrous, Inc. website are subject to individual national regulatory authorization.
 
To view and print a PDF version of the Instructions for Use, click on the appropriate link below to select the product. If you require additional assistance, or to request a hard copy of the Instructions for Use, please Contact Us.
 

Patents and Trademarks

The following Tetrous products and services are protected by patents in the United States and in other jurisdictions of the world. Additionally, Tetrous has licensed some of its technology to various parties in Australia who are also selling products covered by Tetrous patents.  This webpage is provided to satisfy the virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of the America Invents Act and to provide notice under 35 U.S.C. §287(a). The following list of products and services may not be all inclusive, and other products and services not listed here may be protected by one or more patents in the United States and elsewhere. Additional patents may be pending in the United States and elsewhere.

One or more implants, instruments, and/or techniques associated with the product names below may be covered by one or more of the United States Patents indicated:

Product US Patent(s)
EnFix RC™
US 9,486,557, US 9,572,912, US 11,660,373, US 11,759,548

EnFix™, EnFix RC™, Tetrous™ and It’s all about the Enthesis™ are trademarks of Tetrous, Inc. 

Bone Textile™, FormLok™ are trademarks of TheraCell, Inc.

The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, Inc. an Isto Biologics Company.

Tetrous, Inc.

© Tetrous, Inc. All rights reserved.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.